A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C
- 10 December 2008
- journal article
- clinical trial
- Published by Wiley in Liver International
- Vol. 16 (3), 207-210
- https://doi.org/10.1111/j.1600-0676.1996.tb00729.x
Abstract
A randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy and safety of thymosin alpha 1 (alpha 1) in treating chronic hepatitis C. Nineteen Italian patients with chronic active hepatitis C, proven by biopsy were randomly assigned to receive a six month course of thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly) or a placebo. All had HCV-RNA in their serum (by PCR), with serum ALT levels more than double the upper limit of the normal range for at least six months before enrollment. After treatment, patients were followed for an additional six months. All patients completed the trial. One patient treated with thymosin alpha 1, but no patient in the placebo group, normalized serum ALT levels by the end of the treatment. This patient, however, relapsed at the sixth month of the follow up. Overall, there were no significant changes in mean serum ALT levels in either group during the treatment or follow-up period. No patient cleared HCV-RNA. No side effects were reported except for local discomfort at the injection sites, reported by some patients treated with thymosin alpha 1. In conclusion, this regimen of thymosin alpha 1 is not effective in the treatment of chronic hepatitis C.This publication has 17 references indexed in Scilit:
- T-lymphocyte response to hepatitis C virus in different clinical courses of infectionGastroenterology, 1993
- Long-term follow-up of patients with chronic hepatitis C treated with α-interferonHepatology, 1992
- Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology.Proceedings of the National Academy of Sciences of the United States of America, 1992
- Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomised clinical trialsJournal of Hepatology, 1991
- Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytesInternational Journal of Immunopharmacology, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaThe New England Journal of Medicine, 1989
- Thymic hormones ? A clinical updateSpringer Seminars in Immunopathology, 1986
- Induction and augmentation of mitogen‐induced immune interferon production in human peripheral blood lymphocytes by Nα‐desacetylthymosin αlEuropean Journal of Immunology, 1982
- Thymosin Treatment Modulates Production of InterferonJournal of Interferon Research, 1981
- Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide.Proceedings of the National Academy of Sciences of the United States of America, 1977